Anirban Maitra, Laura and Isaac Perlmutter Professor of Pathology, Director, Perlmutter Cancer Center, shared a post on X:
“In Cancer Discovery, Revolution Medicines is out with a preclinical study evaluating RMC-8839, a novel RAS(ON) G13C-selective inhibitor in Lung Cancer.
Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.”
Title: Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer
Authors: William J. McDaid, Helen Adderley, Paolo D. d’Arienzo, Ana Sofia Parreira, Laura C. Woodhouse, Yongxian Zhuang, Sonia Castillo-Lluva, Kirsten L. Tinsley, James Cooksedge, Martin J. Baker, Joshua Searle, Katherine D. Brown, Mathew Carter, Mihaela Aldea, Arianna Marinello, Jacqueline V. Aredo, Nadia Gomez Serra, Maria Bisbe, Philip East, Sophie de Carné Trécesson, Fabrice Barlesi, Marie Wislez, Benjamin Besse, Heather A. Wakelee, Ernest Nadal, Fiona Blackhall, David C. Wedge, Matthew Holderfield, Jacqueline A. M. Smith, Mallika Singh, Kyle J. Seamon, Angeliki Malliri, Colin R. Lindsay
Other articles featuring Anirban Maitra on OncoDaily.